Co-administration of pazopanib and enteral nutrition with omega-3 fatty acids as a safety issue in a patient treated for metastatic clear cell renal cancer: A case report

Pazopanib is an oral multitargeting tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs), approved as the first-line treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) at a fixed dose of 800 mg daily taken fasted. Potential drug-meal...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and therapeutics 2023-01, Vol.19 (2), p.474-476
Main Authors: Zlatović, Josipa Jović, Omrčen, Tomislav, Marijanović, Inga, Kraljević, Marija
Format: Article
Language:English
Subjects:
Cancer
Carcinoma, Renal cell
Carcinoma, Renal Cell - pathology
Care and treatment
Diagnosis
Dietary supplements
Disodium pamidronate
Dosage and administration
Endothelial growth factors
Enteral feeding
Enteral Nutrition
Fatty Acids, Omega-3 - therapeutic use
Health aspects
Humans
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Male
Metastasis
Methods
Middle Aged
Omega-3 fatty acids
Pazopanib
Sarcoma
Tube feeding
Vascular Endothelial Growth Factor A
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pazopanib is an oral multitargeting tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs), approved as the first-line treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) at a fixed dose of 800 mg daily taken fasted. Potential drug-meal interactions and adverse events (AEs) may lack recognition and the related data in literature. We report one case of stomatitis/oral mucositis associated with pazopanib administrated with an oral nutritional supplement enriched with omega-3 fatty acids. The 50-year-old patient with mRCC started pazopanib treatment at standard doses of 800 mg daily as first-line therapy for mRCC, and after a few days, he developed stomatitis. Co-administration of pazopanib with high-fat meals could increase the solubility of highly lipophilic pazopanib, increasing its plasma pazopanib area under the curve (AUC), and maximum concentration (Cmax) above optimal therapeutic level can consequently lead to increased frequency/grade of AEs.
ISSN:0973-1482
1998-4138
DOI:10.4103/jcrt.jcrt_533_22